Om

Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA. The company’s work centers on advancing medicines that may address mild, moderate, and severe forms of sleep apnea through a simplified pill-based approach. Based in Cambridge, Massachusetts, and founded in 2017, Apnimed operates within the biotechnology and sleep medicine markets, where it contributes to the development of new treatment options for patients with chronic breathing disorders during sleep.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I APNIMED MED ENDAVU: Køb Apnimed ($APMD) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Apnimed, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.